Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells
- PMID: 20220779
- DOI: 10.1038/leu.2010.31
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells
Abstract
To gain insight into the molecular pathogenesis of the myelodysplastic syndromes (MDS), we performed global gene expression profiling and pathway analysis on the hematopoietic stem cells (HSC) of 183 MDS patients as compared with the HSC of 17 healthy controls. The most significantly deregulated pathways in MDS include interferon signaling, thrombopoietin signaling and the Wnt pathways. Among the most significantly deregulated gene pathways in early MDS are immunodeficiency, apoptosis and chemokine signaling, whereas advanced MDS is characterized by deregulation of DNA damage response and checkpoint pathways. We have identified distinct gene expression profiles and deregulated gene pathways in patients with del(5q), trisomy 8 or -7/del(7q). Patients with trisomy 8 are characterized by deregulation of pathways involved in the immune response, patients with -7/del(7q) by pathways involved in cell survival, whereas patients with del(5q) show deregulation of integrin signaling and cell cycle regulation pathways. This is the first study to determine deregulated gene pathways and ontology groups in the HSC of a large group of MDS patients. The deregulated pathways identified are likely to be critical to the MDS HSC phenotype and give new insights into the molecular pathogenesis of this disorder, thereby providing new targets for therapeutic intervention.
Similar articles
-
Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.Leukemia. 2010 Apr;24(4):748-55. doi: 10.1038/leu.2009.296. Epub 2010 Feb 4. Leukemia. 2010. PMID: 20130600
-
Conventional and molecular cytogenetic features of myelodysplastic syndrome in China.Exp Oncol. 2007 Dec;29(4):299-303. Exp Oncol. 2007. PMID: 18199987
-
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.Nat Med. 2007 Jan;13(1):78-83. doi: 10.1038/nm1512. Epub 2006 Dec 10. Nat Med. 2007. PMID: 17159988
-
The molecular pathogenesis of the myelodysplastic syndromes.Eur J Haematol. 2015 Jul;95(1):3-15. doi: 10.1111/ejh.12515. Epub 2015 Feb 20. Eur J Haematol. 2015. PMID: 25645650 Review.
-
Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.J Clin Oncol. 2006 Jun 1;24(16):2576-82. doi: 10.1200/JCO.2005.03.6715. J Clin Oncol. 2006. PMID: 16735711 Review.
Cited by
-
The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome.PLoS One. 2012;7(8):e44321. doi: 10.1371/journal.pone.0044321. Epub 2012 Aug 31. PLoS One. 2012. PMID: 22952954 Free PMC article.
-
Consequences of chromosome gain: A new view on trisomy syndromes.Am J Hum Genet. 2022 Dec 1;109(12):2126-2140. doi: 10.1016/j.ajhg.2022.10.014. Am J Hum Genet. 2022. PMID: 36459979 Free PMC article. Review.
-
Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias.Nat Immunol. 2021 Apr;22(4):520-529. doi: 10.1038/s41590-021-00895-4. Epub 2021 Mar 22. Nat Immunol. 2021. PMID: 33753942 Free PMC article.
-
Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes.Cancers (Basel). 2022 Nov 17;14(22):5656. doi: 10.3390/cancers14225656. Cancers (Basel). 2022. PMID: 36428749 Free PMC article. Review.
-
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.Leukemia. 2022 Jul;36(7):1898-1906. doi: 10.1038/s41375-022-01584-3. Epub 2022 May 3. Leukemia. 2022. PMID: 35505182 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous